Dr. Majure on Unmet Needs for Patients With TNBC

Melanie C. Majure, MD
Published: Wednesday, Nov 08, 2017



Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

The biggest challenge facing metastatic TNBC are those patients who are not responding to the available therapies, explains Majure. Many of Majure’s patients frequently contact her because they are not responding to their therapy or their disease is progressing.

There needs to be an agent that targets specific molecular alterations for each patient’s specific tumor type, says Majure.


Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

The biggest challenge facing metastatic TNBC are those patients who are not responding to the available therapies, explains Majure. Many of Majure’s patients frequently contact her because they are not responding to their therapy or their disease is progressing.

There needs to be an agent that targets specific molecular alterations for each patient’s specific tumor type, says Majure.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x